NVCR

NovoCure Ltd

15.59

Oct 21 • 3:59 PM ET -0.12 (-0.76%)

15.59

Aftermarket • 4:15 PM ET 0.00 (0.00%)

Healthcare Medical Devices United Kingdom Small NASD

Peers: DCTH IRTC PROF ARAY MDT ANGO CATX BSX SRTS ICCM

| Held by: VTI IWM VB VBK VXF IWO IBB VTWO SCHA IHI

Scroll to Statements

Index	RUT
Market Cap	1.82B
Enterprise Value	1.60B
Income	-148.56M
Sales	699.19M
Book/sh	2.90
Cash/sh	3.87
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	1605
IPO	Oct 02, 2015

P/E	-
Forward P/E	-
PEG	-
P/S	2.60
P/B	5.37
P/C	4.03
P/FCF	-
EV/EBITDA	-
EV/Sales	2.29
Quick Ratio	2.70
Current Ratio	2.89
Debt/Eq	0.69
LT Debt/Eq	0.69
Option/Short	Yes / Yes

EPS (ttm)	-1.31
EPS next Y	-0.81
EPS next Q	-0.23
EPS this Y	-1.23%
EPS next Y	34.71%
EPS next 5Y	32.69%
EPS past 3/5Y	-11.40% -
Sales past 3/5Y	6.81% 5.80%
EPS Y/Y TTM	16.12%
Sales Y/Y TTM	10.95%
EPS Q/Q	62.48%
Sales Q/Q	15.60%
Earnings	Oct 29 BMO
EPS/Sales Surpr.	60.78% 6.46%

Insider Own	10.11%
Insider Trans	-0.46%
Inst Own	90.54%
Inst Trans	5.70%
ROA	-14.56%
ROE	-43.22%
ROIC	-26.00%
Gross Margin	76.13%
Oper. Margin	-22.08%
Profit Margin	-21.25%
SMA20	3.30%
SMA50	-4.11%
SMA200	5.22%
Trades

Shs Outstand	116.44M
Shs Float	104.67M
Short Float	10.67%
Short Ratio	7.58
Short Interest	11.16M
52W High	21.45 -27.32%
52W Low	9.82 58.76%
Volatility	4.85% 4.42%
ATR (14)	0.70
RSI (14)	52.34
Beta	1.07
Rel Volume	1.76
Avg Volume	1.47M
Volume	2,594,896

Perf Week	12.64%
Perf Month	-6.48%
Perf Quarter	-22.01%
Perf Half Y	19.74%
Perf YTD	20.57%
Perf Year	10.33%
Perf 3Y	7.07%
Perf 5Y	-87.22%
Perf 10Y	127.92%
Recom	1.86
Target Price	26.86
Prev Close	15.71
Price	15.59
Change %	-0.76%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-13-26	Resumed	JP Morgan	Neutral	$17
Jul-25-25	Downgrade	Wells Fargo	Overweight → Equal Weight	$14.50
Jul-08-25	Initiated	Ladenburg Thalmann	Buy	$30
Dec-02-24	Upgrade	Evercore ISI	In-line → Outperform	$18 → $30
Oct-16-24	Upgrade	H.C. Wainwright	Neutral → Buy	$24 → $30
Nov-20-23	Resumed	JP Morgan	Neutral	$15
Aug-28-23	Downgrade	H.C. Wainwright	Buy → Neutral	$85 → $25
Aug-08-23	Upgrade	Piper Sandler	Neutral → Overweight	$45
Aug-04-23	Initiated	SVB Securities	Outperform	$51
Jul-31-23	Upgrade	Evercore ISI	Underperform → In-line	$33
Jun-07-23	Upgrade	Wedbush	Underperform → Neutral	$53 → $46
May-16-23	Upgrade	Wells Fargo	Equal Weight → Overweight	$70 → $104
Mar-17-23	Downgrade	JP Morgan	Neutral → Underweight	$99 → $50
Jan-06-23	Downgrade	Wells Fargo	Overweight → Equal Weight	$89 → $107
Jan-05-23	Reiterated	H.C. Wainwright	Buy	$100 → $140
Nov-29-22	Upgrade	Wells Fargo	Equal Weight → Overweight	$74 → $89
Oct-24-22	Downgrade	Piper Sandler	Overweight → Neutral	$90 → $70
Jul-05-22	Downgrade	Evercore ISI	In-line → Underperform
May-16-22	Initiated	H.C. Wainwright	Buy	$115
Feb-08-22	Initiated	Loop Capital	Buy	$200

Show Previous Ratings

Today 01:32PM	Novocure Must Show Its Breakout Second Quarter Was A Trend, Not A One-Off (Earnings Whispers)
Oct-01-26 09:00AM	Novocures Optune Pax Receives Approval in Japan for the Treatment of Unresectable Locally Advanced Pancreatic Cancer (Business Wire)
07:00AM	Novocure to Report Third Quarter 2026 Financial Results (Business Wire)
Sep-02-26 07:00AM	Novocure Announces Upcoming Investor Events (Business Wire)
Aug-14-26 05:54PM	Which Medtech Giant Would Buy Inspire Medical Systems? (Trefis)
08:30AM	Loading…
Jul-24-26 08:30AM	NovoCure Limited Q2 2026 Earnings Call Summary (Moby) -11.71%
Jul-23-26 11:45PM	Why Did CSX, UNP, NVCR Stocks Surge To 52-Week Highs Today? (Stocktwits) +28.39%
04:09PM	NVCR Stock Surges 28% For Best Day In Over 1.5 Years Whats Driving The Rally? (Stocktwits)
03:01PM	NovoCure Ltd (NVCR) Q2 2026 Earnings Call Highlights: Record Revenue and Strategic Growth Amid ... (GuruFocus.com)
11:33AM	Novocure Reports Record Second-Quarter Revenue as Optune Expansion Drives Higher 2026 Outlook (InvestorsHub)
10:58AM	Novocure Flashes A Bullish Signal As It Breaks Out; Have Shares 'Turned A Corner?' (Investor's Business Daily)
07:07AM	NovoCure: Q2 Earnings Snapshot (Associated Press)
07:00AM	Novocure Reports Second Quarter 2026 Financial Results (Business Wire)
Jul-01-26 07:00AM	Novocure to Report Second Quarter 2026 Financial Results (Business Wire)
Jun-30-26 07:00AM	Novocure's Optune Pax Receives CE Mark for the Treatment of Locally Advanced Pancreatic Cancer (Business Wire)
04:09PM	Loading…
Jun-18-26 04:09PM	Novocure Tumbles After Cancer-Fighting Medical Device Flops In Brain Cancer (Investor's Business Daily) -20.00%
12:04PM	Novocures Optune Gio fails to show benefit at earlier stage (Medical Device Network)
08:53AM	Novocure Shares Slide After Phase 3 Glioblastoma Study Falls Short of Survival Goal (InvestorsHub)
08:22AM	FreeCast surges premarket; Accenture, Novocure slide (Investing.com)
07:00AM	Novocure Announces Topline Data from the Phase 3 TRIDENT Trial Evaluating Earlier Use of Tumor Treating Fields Therapy in Newly Diagnosed Glioblastoma (Business Wire)
06:55AM	Pfizer CFO to step down; Denali sells a regulatory fast-pass (BioPharma Dive)
May-04-26 04:29PM	NovoCure Stock Shows Strength With RS Upgrade; Investors Should Watch For Next Entry (Investor's Business Daily) -6.20%
Apr-30-26 08:45PM	NovoCure Limited Q1 2026 Earnings Call Summary (Moby) +27.49% +9.27%
01:12PM	Two Medical Stocks Skyrocket After Demolishing Views - And One Is About To Break Out (Investor's Business Daily)
07:23AM	NovoCure: Q1 Earnings Snapshot (Associated Press)
07:00AM	Novocure Reports First Quarter 2026 Financial Results (Business Wire)
Apr-01-26 07:00AM	Novocure to Report First Quarter 2026 Financial Results (Business Wire)
Mar-26-26 07:00AM	Novocure Announces Positive Topline Results from Phase 2 PANOVA-4 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Metastatic Pancreatic Cancer (Business Wire)
Mar-09-26 11:53AM	Novocure's Optune Lua Gets Japan Reimbursement for NSCLC Treatment (Zacks)
Mar-02-26 09:15AM	NovoCure (NVCR) Reliance on International Sales: What Investors Need to Know (Zacks)
07:00AM	Loading…
07:00AM	Novocure Announces Optune Lua Receives Reimbursement Approval in Japan for the Treatment of Non-Small Cell Lung Cancer (Business Wire)
Feb-27-26 04:30PM	Novocure to Participate in 2026 Leerink Global Healthcare Conference (Business Wire)
Feb-26-26 04:34PM	NovoCure Limited Q4 2025 Earnings Call Summary (Moby) -8.27%
04:14PM	NovoCure Ltd (NVCR) Q4 2025 Earnings Call Highlights: Record Revenue and Strategic Growth Plans ... (GuruFocus.com)
12:15PM	NovoCure (NVCR) Reports Q4 Loss, Beats Revenue Estimates (Zacks)
09:04AM	NovoCure Q4 Earnings Call Highlights (MarketBeat)
07:39AM	NovoCure: Q4 Earnings Snapshot (Associated Press Finance)
07:00AM	Novocure Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Company Update (Business Wire)
Feb-25-26 09:00AM	Immuno-Oncology Investments Accelerate as Pipeline Catalysts Multiply in 2026 (PR Newswire) +27.68%
Feb-24-26 07:00AM	Tumor Treating Fields (TTFields) Therapy to be Covered for Patients with Newly Diagnosed Glioblastoma Through British Columbia Cancer (BC Cancer) (Business Wire) +6.92%
Feb-19-26 10:00AM	Will NovoCure (NVCR) Report Negative Earnings Next Week? What You Should Know (Zacks)
Feb-17-26 11:17AM	New Treatment Modalities Are Reaching Cancers That Resisted Everything Else (PR Newswire)
10:01AM	Novocure Gains FDA Approval for Optune Pax to Treat Pancreatic Cancer (Zacks)
Feb-13-26 07:42AM	Novocures stock rises 37% on FDA clearance of pancreatic cancer treatment device (Medical Device Network) -12.29%
06:00AM	Lyell starts first-of-its-kind CAR-T trial; New coalition aims to boost European biotechs (BioPharma Dive)
Feb-12-26 05:43PM	Novocure Is Up 19%. FDA Approval Is Giving the Biotech Stock a Lift. (Barrons.com) +19.33%
04:35PM	These Stocks Are Todays Movers: AppLovin, Fastly, Micron, Cisco, QuantumScape, Novocure, AST SpaceMobile, and More (Barrons.com)
04:15PM	Stocks to Watch Thursday Recap: Cisco, McDonalds, AppLovin (The Wall Street Journal)
03:11PM	Stock Market Today: S&P 500 Breaks Key Support As Techs Pace Sell-Off; Cancer Stock Vaults (Live Coverage) (Investor's Business Daily)
11:26AM	NovoCure Stock Surges After FDA Approves Optune Pax (Benzinga)
10:07AM	Stocks to Watch Thursday: Cisco, McDonald's, AppLovin (The Wall Street Journal)
06:53AM	This Biotech Stock Is Jumping 25% After Getting an FDA Boost (Barrons.com)
06:28AM	AppLovin shares slide after earnings, and other early market movers (MarketWatch)
06:19AM	Stock Market Today: Dow Jones, S&P 500 Futures Gain After Strong Job Report-Micron, Novocure, Fastly In Focus (Benzinga)
04:50AM	Stock Market Today: Dow, S&P 500 and Nasdaq point higher as tech finds its footing; Treasurys steady; precious metals dip. (MarketWatch)
Feb-11-26 09:55PM	NovoCure (NVCR) Stock Is Trending Overnight - Here's What You Should Know (Benzinga)
06:33PM	Novocure Gets FDA Approval for Pancreatic Cancer Treatment; Shares Soar (The Wall Street Journal)
05:54PM	U.S. FDA Approves Novocure's Optune Pax for the Treatment of Locally Advanced Pancreatic Cancer (Business Wire)
Feb-05-26 08:10AM	Bristol Myers Squibb (BMY) Tops Q4 Earnings and Revenue Estimates (Zacks) -12.72%
Jan-12-26 07:00AM	Novocure Announces Preliminary Full Year and Fourth Quarter 2025 Performance and Provides Company Update (Business Wire)
Jan-07-26 03:58AM	Moderna (MRNA) Soars 10.9%: Is Further Upside Left in the Stock? (Zacks)
Dec-22-25 07:00AM	Novocure to Present at 44th Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-09-25 05:31AM	Medtronic changes investor relations leadership ahead of diabetes spinout (MedTech Dive) +5.31%
Dec-01-25 07:00AM	Novocure Appoints Company President Frank Leonard as Chief Executive Officer (Business Wire) -8.82%
Nov-26-25 07:00AM	Novocure to Participate in 37th Annual Piper Sandler Healthcare Conference (Business Wire)
Nov-12-25 10:00AM	2 Healthcare Stocks for Individual Investors With a 40-Year Time Horizon (Motley Fool)
07:00AM	Novocure to Participate in 2025 Jefferies Global Healthcare Conference (Business Wire)
Oct-30-25 04:22PM	NovoCure Ltd (NVCR) Q3 2025 Earnings Call Highlights: Revenue Growth Amidst Challenges (GuruFocus.com)
10:30AM	Compared to Estimates, NovoCure (NVCR) Q3 Earnings: A Look at Key Metrics (Zacks)
08:20AM	NovoCure (NVCR) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
07:17AM	NovoCure: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	Novocure Reports Third Quarter 2025 Financial Results (Business Wire)
Oct-15-25 07:00AM	Novocure to Present New Research for Tumor Treating Fields (TTFields) Therapy at European Association of Neuro-Oncology (EANO) Meeting and the European Society for Medical Oncology (ESMO) Congress (Business Wire) +7.67%
Oct-01-25 07:00AM	Novocure to Report Third Quarter 2025 Financial Results (Business Wire) +8.20%
Sep-29-25 04:30PM	Novocure to Present Final Results from the Pivotal Phase 3 METIS Trial of its Tumor Treating Fields (TTFields) Therapy for Brain Metastases from Non-Small Cell Lung Cancer at 2025 ASTRO Annual Meeting (Business Wire)
Sep-16-25 05:28AM	Novocure obtains approval for Optune Lua device in Japan to treat NSCLC (Medical Device Network)
Sep-15-25 07:00AM	Novocure's Optune Lua Receives Approval in Japan for the Treatment of Unresectable Advanced/Recurrent Non-Small Cell Lung Cancer (NSCLC) (Business Wire)
Aug-29-25 04:26AM	2 Beaten-Down Stocks That Could Rocket 142% to 222% Higher, According to Wall Street Analysts (Motley Fool)
Aug-28-25 07:00AM	Novocure Announces Upcoming Investor Events (Business Wire)
Aug-25-25 07:00AM	Novocure Announces Coverage of Tumor Treating Fields (TTFields) Therapy for Patients with Newly Diagnosed Glioblastoma in Spain (Business Wire) -5.87%
Aug-22-25 01:37PM	NVCR Stock Slips Despite PMA Application to Treat Pancreatic Cancer (Zacks)
Aug-20-25 07:00AM	Novocure Submits Premarket Approval Application to FDA for Tumor Treating Fields Therapy in Locally Advanced Pancreatic Cancer (Business Wire)
Aug-13-25 12:08PM	Leerink Partners Reiterates a Buy Rating on NovoCure Limited (NVCR) (Insider Monkey)
Jul-25-25 07:02AM	NovoCure: Q2 Earnings Snapshot (Associated Press Finance)
Jul-24-25 01:30PM	NovoCure (NVCR) Reports Q2 Earnings: What Key Metrics Have to Say (Zacks) -24.05%
08:05AM	NovoCure (NVCR) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
07:00AM	Novocure Reports Second Quarter 2025 Financial Results (Business Wire)
Jul-01-25 07:00AM	Novocure to Present Final Secondary Endpoint Data from the Phase 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) in Pancreatic Cancer at the ESMO Gastrointestinal Cancers Congress 2025 (Business Wire)
Jun-30-25 09:32AM	NovoCure (NVCR) Soars 5.3%: Is Further Upside Left in the Stock? (Zacks)
07:00AM	Novocure to Report Second Quarter 2025 Financial Results (Business Wire)
Jun-18-25 12:00PM	What Makes NovoCure (NVCR) a New Buy Stock (Zacks)
Jun-06-25 12:26PM	NVCR Stock Dips Despite Positive OS Data From Phase 3 PANOVA-3 Trial (Zacks)
Jun-02-25 02:05PM	NovoCure's Tumor Treating Fields Boost One-Year And Pain-Free Survival In Pancreatic Cancer Trial (Benzinga) -10.83%
May-31-25 03:08PM	Zai Lab and Novocure Announce Results From the Phase 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting (Business Wire)
08:00AM	Results From the Phase 3 PANOVA-3 Trial of Novocure's Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting (Business Wire)
May-28-25 06:57AM	1 Stock Down 35% This Year You'll Regret Not Buying on the Dip, According to Wall Street (Motley Fool)
May-27-25 07:00AM	Novocure Announces Upcoming Investor Events (Business Wire)
May-16-25 10:00AM	The Next Frontier to Treat Cancer: Electricity (The Wall Street Journal)
May-15-25 09:55AM	Does NovoCure (NVCR) Have the Potential to Rally 105.5% as Wall Street Analysts Expect? (Zacks)
Apr-29-25 09:55AM	Wall Street Analysts See a 91.92% Upside in NovoCure (NVCR): Can the Stock Really Move This High? (Zacks)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
NICOLAS LEUPIN	Officer	Jul 23 '26	Proposed Sale	15.57	39,088	608,600		Jul 23 04:21 PM
Leonard Frank X	Chief Executive Officer	Jun 04 '26	Sale	17.93	34,273	614,635	459,520	Jun 05 04:28 PM
FRANCIS LEONARD	Officer	Jun 04 '26	Proposed Sale	17.93	34,273	614,635		Jun 04 05:41 PM
LEUNG GABRIEL	Director	Jun 02 '26	Sale	15.77	2,945	46,445	89,499	Jun 03 04:54 PM
Stafford Kristin	Director	Jun 02 '26	Sale	15.77	2,945	46,445	11,324	Jun 03 04:53 PM
Ocean Allyson J	Director	Jun 02 '26	Sale	15.77	2,945	46,445	11,324	Jun 03 04:53 PM
Scannell Timothy J	Director	Jun 02 '26	Sale	15.77	2,945	46,445	14,288	Jun 03 04:53 PM
HILLEMAN JERYL L	Director	Jun 02 '26	Sale	15.77	2,945	46,445	13,861	Jun 03 04:53 PM
VERNON W ANTHONY	Director	Jun 02 '26	Sale	15.77	2,945	46,445	197,657	Jun 03 04:52 PM
Hung David	Director	Jun 02 '26	Sale	15.77	2,945	46,445	20,465	Jun 03 04:52 PM
VERNON W ANTHONY	Director	Apr 28 '26	Option Exercise	11.39	21,500	244,885	200,602	Apr 28 04:27 PM
Leupin Nicolas	Former Chief Medical Officer	Mar 04 '26	Sale	13.31	1,100	14,636	102,979	Mar 05 04:33 PM
Weinberg Uri	Chf Medical and Innovation Ofr	Mar 04 '26	Sale	13.31	6,412	85,314	267,190	Mar 05 04:32 PM
Brackmann Christoph	Chief Financial Officer	Mar 04 '26	Sale	13.31	6,412	85,314	182,842	Mar 05 04:31 PM
Leonard Frank X	Chief Executive Officer	Mar 04 '26	Sale	13.31	5,607	74,603	493,793	Mar 05 04:31 PM
Paravasthu Mukund	Chief Operating Officer	Mar 05 '26	Sale	13.77	43,246	595,670	72,832	Mar 05 04:31 PM
Paravasthu Mukund	Chief Operating Officer	Mar 04 '26	Sale	13.31	5,377	71,543	116,078	Mar 05 04:31 PM
Puri Michal Nath	Chief Human Resources Officer	Mar 04 '26	Sale	13.31	1,100	14,636	201,322	Mar 05 04:31 PM
DOYLE WILLIAM F	Executive Chairman	Mar 03 '26	Sale	12.98	71,887	932,883	328,397	Mar 05 04:30 PM
MUKUND PARAVASTHU	Officer	Mar 05 '26	Proposed Sale	13.77	43,246	595,682		Mar 05 04:06 PM
CHRISTOPH BRACKMANN	Officer	Mar 04 '26	Proposed Sale	13.31	6,412	85,314		Mar 04 05:54 PM
URI WEINBERG	Officer	Mar 04 '26	Proposed Sale	13.31	6,412	85,314		Mar 04 05:53 PM
MUKUND PARAVASTHU	Officer	Mar 04 '26	Proposed Sale	13.31	5,377	71,543		Mar 04 05:42 PM
FRANCIS LEONARD	Officer	Mar 04 '26	Proposed Sale	13.31	5,607	74,603		Mar 04 05:13 PM
WILLIAM DOYLE	Officer	Mar 03 '26	Proposed Sale	12.98	71,887	932,885		Mar 03 05:01 PM
Weinberg Uri	Chf Medical and Innovation Ofr	Feb 27 '26	Sale	13.84	7,461	103,257	213,757	Mar 03 04:11 PM
Weinberg Uri	Chf Medical and Innovation Ofr	Mar 02 '26	Sale	13.33	3,272	43,607	223,477	Mar 03 04:11 PM
Puri Michal Nath	Chief Human Resources Officer	Feb 27 '26	Sale	13.66	1,441	19,690	162,322	Mar 03 04:10 PM
Leonard Frank X	Chief Executive Officer	Feb 27 '26	Sale	13.66	9,734	133,003	338,011	Mar 03 04:09 PM
Leonard Frank X	Chief Executive Officer	Mar 02 '26	Sale	13.49	7,232	97,581	349,400	Mar 03 04:09 PM
FRANCIS LEONARD	Officer	Mar 02 '26	Proposed Sale	13.49	7,232	97,581		Mar 02 05:40 PM
URI WEINBERG	Officer	Mar 02 '26	Proposed Sale	13.33	3,272	43,607		Mar 02 04:14 PM
FRANCIS LEONARD	Officer	Feb 27 '26	Proposed Sale	13.66	9,734	133,003		Feb 27 05:13 PM
URI WEINBERG	Officer	Feb 27 '26	Proposed Sale	13.84	7,461	103,257		Feb 27 04:19 PM

NovoCure Ltd. is an oncology company which engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. Its platform is called the Tumor Treating Field which uses electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. The company was founded by Yoram Palti in 2000 and is headquartered in St. Helier, the United Kingdom.

Executive ChairmanMr. William F. Doyle

CEO & DirectorMr. Frank Leonard

Chief Financial OfficerMr. Christoph Brackmann

Chief Human Resources OfficerMr. Michael Puri

Ph.D.Dr. Uri Weinberg M.D.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

NVCR

NovoCure Ltd

Upgrade your Finviz experience